Therapeutic use of small molecule MET inhibitors has been approved for use in medullary thyroid, renal cell and subsets of nonsmall cell lung carcinomas, but have failed to demonstrate clinical efficacy for other cancer types including CRC due to inappropriate patient selection [6]. Here, MET is linked to colorectal carcinoma.